Adults 18 to 55, any sex, with Depression or Anxiety. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in BOLD (Blood-oxygen-level-dependent) Mean Signal Change From Baseline to 12 Weeks in Response to Emotional (vs. Neutral) Word StimuliPrimary· Baseline to 12 weeks
fMRI BOLD response to emotional word stimuli baseline to 12 weeks (post-MBCT). BOLD signal change (pre- to post-MBCT) is estimated from the contrast of emotional word vs neutral words, and extracted from voxels within the fronto-parietal and default mode areas at baseline and 12-weeks. Significant Voxel-wise BOLD activity is reported using z-scores from peak voxels. A mean score was calculated based on z-score and SD of 2 in the context of reporting fMRI BOLD data here. Z-scores is a statistical measure that describes how many standard deviations a data point (e.g., a voxel's signal) is from t
BOLD - Right Frontopolar Cortex |
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
2.315
± .5
BOLD - Right Dorsolateral PFC |
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
2.13
± .5
BOLD - Left Precuneus |
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
-2.255
± .5
Amplitude of P1 Event-related Potentials (ERP) in Response to Threat (vs. Neutral) Face Cues Pre- to Post-MBCTSecondary· Baseline to 12 weeks (pre- to post-MBCT)
P1 Evoked event-related electrical potentials (ERP) amplitudes elicited from specific emotional threat vs. neutral stimuli were primary outcome. An 80-150 ms search window at EEG electrode P8 was used to identify the P1 peak, \& mean value around peaks (50 ms) was exported for analysis. Mean P1-Cue amplitudes were analyzed pre- to post-MBCT to determine the effects of time (pre to post-MBCT), emotion (angry vs. happy), and congruency (congruent vs. incongruent). Mean P1-Cue amplitudes in microvolts and SD for each condition are summarized below.
Mean amplitude (uv) and standard deviations for Angry Cues pre-MBCT
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
2.62
± 2.83
Mean amplitude (uv) and standard deviations for Angry Cues post-MBCT
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
2.60
± 2.74
Mean amplitude (uv) and standard deviations for Happy Cues pre-MBCT
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
2.68
± 2.81
Mean amplitude (uv) and standard deviations for Happy Cues post-MBCT
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
2.58
± 2.73
Mean amplitude (uv) and standard deviations for Angry Congruent Cues pre-MBCT
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
1.19
± 2.32
Mean amplitude (uv) and standard deviations for Angry Congruent Cues post-MBCT
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
.87
± 1.97
Mean amplitude (uv) and standard deviations for Angry Incongruent Cues pre-MBCT
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
1.16
± 2.30
Mean amplitude (uv) and standard deviations for Angry Incongruent Cues post-MBCT
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
.61
± 2.24
Response Time to Probes as a Function of Emotion and Congruency in the Dot Probe TaskSecondary· Baseline to ~12 weeks
Effects of time (pre-MBCT versus post-MBCT), emotion (angry versus happy), and congruency (congruent probes versus incongruent probes) on reaction time (RT) was measured in mild to moderate depression/anxiety group.
RT to probes congruent with angry emotional stimuli pre-MBCT | unit of measure: mean RT & SE)
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
303.50
± 1.2
RT to probes congruent with angry emotional stimuli post-MBCT | unit of measure: mean RT & SE
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
298.30
± 1.2
RT to probes incongruent with angry emotional stimuli pre-MBCT | unit of measure: mean RT & SE
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
304.51
± 1.3
RT to probes incongruent with angry emotional stimuli post-MBCT | unit of measure: mean RT & SE
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
301.29
± 1.5
RT to probes congruent with happy emotional stimuli pre-MBCT | unit of measure: mean RT & SE
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
301.47
± 1.4
RT to probes congruent with happy emotional stimuli post-MBCT | unit of measure: mean RT & SE
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
297.5
± 1.3
RT to probes incongruent with happy emotional stimuli pre-MBCT | unit of measure: mean RT & SE
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
304.22
± 1.2
RT to probes incongruent with happy emotional stimuli post-MBCT | unit of measure: mean RT & SE
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
301.38
± 1.1
Self-report Psychological Measures of Anxiety and Stress Pre- to Post-Mindfulness TrainingSecondary· Baseline to ~12 weeks pre- to post-MBCT (depression/anxiety cohort)
The Depression \& Anxiety Stress Scale (DASS-Anxiety) (Lovibond and Lovibond, 1995) is a 7-item measure designed to assess symptoms of fear and autonomic arousal. Items are rated on a 4-point scale, ranging from 0 (did not apply to me at all) to 3 (applied to me very much or most of the time), and summed to compute the total scale (range 0-21). Higher scores are indicative of greater symptom severity, with scores greater than 10 typically considered of clinical significance. The DASS-Depression is a 7-item measure designed to assess dysphoric mood. Items are rated on a 4-point Likert scale, ra
DASS-D scores pre- to post-MBCT | Mean change scores, (SE)
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
7.96
± 1.41
DASS-A mean change pre- to post-MBCT | mean change, (SE)
Group
Value
95% CI
Mild to Moderate Depression and/or Anxiety
3.68
± 1.28
Self-report Psychological Measures of Stress Pre- to Post-Mindfulness TrainingSecondary· Baseline to ~12 weeks pre- to post-MBSR (high stress cohort)
The Perceived Stress Scale (PSS-14) is a 14-item scale, with a total range from 0 (no symptoms) to 56 (highest severity) Higher scores are indicative of greater symptom severity, with scores greater than 10 typically considered of clinical significance.
Group
Value
95% CI
High Stress
-7.4
± 2.3
Sponsor's own description
Mindfulness-based Interventions (MBIs) are a family of standardized cognitive and behavioral therapies that focus on cultivating mindfulness-related skills for improving maladaptive cognitive, emotional, and behavioral processes. MBIs have been developed for a wide range of problems, disorders, and populations and are increasingly available in a variety of health settings. This mixed methods study proposes to investigate proposed neurobiological, physiological, psycho-social-behavioral, and cognitive mechanisms by which MBIs may improve health outcomes.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
Other trials of Mindfulness-based Cognitive Therapy (MBCT)
Trials testing the same drug.
NCT05111665 — Decentering and Relapse/Recurrence in MBCT for Depression in Adults
· NA
· completed
Other recruiting trials for Depression
Currently open trials in the same condition.
NCT07336238 — Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or
· Phase 2
· recruiting
NCT06906939 — A Randomized Pilot rTMS Trial for Knee Arthritis Pain and Depression
· EARLY_PHASE1
· recruiting
NCT07517549 — Sexual Health Education During Pregnancy
· NA
· recruiting
NCT06408246 — ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression
· Phase 2
· recruiting
NCT07449676 — Effects of an Innovative TCM-based Tui Jing Therapy on Psychological and Neurophysiological Functions in Depression
· NA
· recruiting
Other Vanderbilt University Medical Center trials
Trials by the same sponsor.
NCT07005037 — Swallowing Impairments in ICU Survivors and Community-Dwelling Adults
· not yet recruiting
NCT07527273 — Cognitive Enhancement in Recurrent Depression (The COG-D-R Study)
· NA
· not yet recruiting
NCT07295288 — Botox Injections in Non-Cranial Nerve VII Innervated Muscles for Facial Synkinesis
· Phase 4
· not yet recruiting
NCT07431541 — Topical Carboxytherapy Paste Following Microneedling
· Phase 1, PHASE2
· not yet recruiting
NCT07224711 — The Impact of Perioperative Lidocaine Infusions on Enhanced Recovery After Non-Cardiac Surgery
· Phase 4
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vanderbilt University Medical Center
Last refreshed: 31 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03571386.